RT Journal Article SR Electronic T1 A Comprehensive Clinical Description of Pediatric SARS-CoV-2 Infection in Western Pennsylvania JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.12.14.20248192 DO 10.1101/2020.12.14.20248192 A1 Megan Culler Freeman A1 Kristina Gaietto A1 Leigh Anne DiCicco A1 Sherry Rauenswinter A1 Joseph R. Squire A1 Zachary Aldewereld A1 Glenn Rapsinski A1 Jennifer Iagnemma A1 Brian T. Campfield A1 David Wolfson A1 Traci M. Kazmerski A1 Erick Forno YR 2020 UL http://medrxiv.org/content/early/2020/12/16/2020.12.14.20248192.abstract AB Objective We sought to characterize clinical presentation and healthcare utilization for pediatric COVID-19 in Western Pennsylvania (PA).Methods We established and analyzed a registry of pediatric COVID-19 in Western PA that includes cases in patients <22 years of age cared for by the pediatric quaternary medical center in the area and its associated pediatric primary care network from March 11 through August 20, 2020.Results Our cohort included 424 pediatric COVID-19 cases (mean age 12.5 years, 47.4% female); 65% reported exposure and 79% presented with symptoms. The most common initial healthcare contact was through telehealth (45%). Most cases were followed as outpatients, but twenty-two patients (4.5%) were hospitalized: 19 with acute COVID-19 disease, and three for multisystem inflammatory syndrome of children (MIS-C). Admitted patients were younger (p<0.001) and more likely to have pre-existing conditions (p<0.001). Black/Hispanic patients were 5.8 times more likely to be hospitalized than white patients (p=0.012). Five patients (1.2%) were admitted to the PICU, including all three MIS-C cases; two required BiPAP and one mechanical ventilation. All patients survived.Conclusions We provide a comprehensive snapshot of pediatric COVID-19 disease in an area with low to moderate incidence. In this cohort, COVID-19 was generally a mild disease; however, ∼5% of children were hospitalized. Pediatric patients can be critically ill with this infection, including those presenting with MIS-C.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Clinical and Translational Science Institute, University of Pittsburgh supported by the National Institutes of Health/National Center for Advancing Translational Sciences [grant number UL1-TR-001857], the Pediatric Infectious Disease Society and St. Jude Children Research Hospital Fellowship Program in Basic and Translational Research to MCF, the National Institutes of Health/ National Heart, Lung, and Blood Institute [grant number T32-HL129949] to KMG, the Pediatric Scientist Development Program (PSDP) sponsored by the Association of Medical School Pediatric Department Chairs (AMSPDC) funded by the National Institutes of Health/ National Institute of Child Health and Human Development [grant K12HD000850-34] to GJR, and the National Institute of Health/National Heart, Lung, and Blood Institute [grant number R01-HL149693] to EF. The authors do not have any conflicts of interest to declare related to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient information was securely handled as approved by the institutional review board at the University of Pittsburgh (Protocol # STUDY20030250). All data were deidentified prior to analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAdditional data available upon request.